PEMBROLIZUMAB - Emerging Insight and Market Forecast - 2030

PEMBROLIZUMAB - Emerging Insight and Market Forecast - 2030

  • February 2021 •
  • 30 pages •
  • Report ID: 6025054 •
  • Format: PDF
“PEMBROLIZUMAB - Emerging Insight and Market Forecast - 2030” the report provides comprehensive insights about an investigational product for Follicular lymphoma in 7 Major Markets. A detailed picture of the PEMBROLIZUMAB in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020 - 2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

PEMBROLIZUMAB (Keytruda) is a humanized monoclonal antibody designed to inhibit the PD-1 co-inhibitory receptor. The interaction between PD-1 and its primary ligand, PD-L1, inhibits T-cell proliferation and survival, and induces apoptosis of tumor-specific T-cells. The disruption of this interaction reduces the ability of the tumor to evade immune system targeting and enhances antitumor immune responses. It is being developed by Merck and is currently in Phase II for follicular lymphoma.

Scope of the report
The report provides insights into:
• A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
• Elaborated details on regulatory milestones and other development activities have been provided in this report.
• The report also highlights the drug research and development activity details across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around PEMBROLIZUMAB.
• The report contains forecasted sales for PEMBROLIZUMAB till 2030.
• Comprehensive coverage of the late-stage emerging therapies (Phase III) for Follicular lymphoma.
• The report also features the SWOT analysis with analyst insights and key findings of PEMBROLIZUMAB.

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
PEMBROLIZUMAB Analytical Perspective
• In-depth PEMBROLIZUMAB Market Assessment
This report provides a detailed market assessment of PEMBROLIZUMAB in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

• PEMBROLIZUMAB Clinical Assessment
The report provides the clinical trials information of PEMBROLIZUMAB covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights
• In the coming years, the market scenario for Follicular lymphoma is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence PEMBROLIZUMAB dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Other emerging products for Follicular lymphoma are giving market competition to PEMBROLIZUMAB and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of PEMBROLIZUMAB.
• Our in-depth analysis of the forecasted sales data of PEMBROLIZUMAB from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the PEMBROLIZUMAB.

Key Questions
• Which company is developing PEMBROLIZUMAB along with the phase of the clinical study?
• What is the technology utilized in the development of PEMBROLIZUMAB?
• What is the product type, route of administration and mechanism of action of PEMBROLIZUMAB?
• What is the clinical trial status of the study and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the PEMBROLIZUMAB development?
• What are the key designations that have been granted to PEMBROLIZUMAB?
• What is the forecasted market scenario of PEMBROLIZUMAB?
• What is the history of PEMBROLIZUMAB and what is its future?
• What is the forecasted sales of PEMBROLIZUMAB in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how these are giving competition to PEMBROLIZUMAB?
• Which are the late-stage emerging therapies under development for the treatment of the Follicular Lymphoma?